Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

26,182 signal articles · 235 in last 24h · 125,804 total before filter · latest 19m ago
235last 24h
1176last 7d
164● bullish (7d)
129● bearish (7d)
205publishers
AllMacro225Earnings409M&A93Regulatory21Product9Analyst10
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Palo Alto Networks Hits $10B Revenue Run Rate Beats S&P 500 Across All Timeframes
24/7 Wall St.78d agobullish
Palo Alto Networks Hits $10B Revenue Run Rate Beats S&P 500 Across All Timeframes

From Firewall Vendor to AI Security Platform A decade ago, Palo Alto Networks (NASDAQ: PANW) was still primarily known as a next-generation firewall company competing with legacy network security incumbents. The transformation since then has been dramatic. Under CEO Nikesh Arora, the company pivoted into a sprawling cybersecurity platform spanning network, cloud, security operations, identity, ... Palo Alto Networks Hits $10B Revenue Run Rate Beats S&P 500 Across All Timeframes

3 Reasons to Avoid HIMX and 1 Stock to Buy Instead
StockStory78d agobullish
3 Reasons to Avoid HIMX and 1 Stock to Buy Instead

Himax has been on fire lately. In the past six months alone, the company’s stock price has rocketed 118%, reaching $20.35 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

The Bull Case For Johnson & Johnson (JNJ) Could Change Following Key Oncology And Immunology Pipeline Wins - Learn Why
Simply Wall St.78d agobullish
The Bull Case For Johnson & Johnson (JNJ) Could Change Following Key Oncology And Immunology Pipeline Wins - Learn Why

In recent weeks, Johnson & Johnson reported positive late‑stage data and regulatory milestones across multiple therapies, including TECVAYLI in relapsed/refractory multiple myeloma, amivantamab-based regimens in lung and head and neck cancers, and a TREMFYA label update in psoriatic arthritis. These advances, alongside progress for nipocalimab in systemic lupus erythematosus and Sjögren's disease and expanded frontline use of Darzalex in the UK, highlight how Johnson & Johnson is broadening...

Broadcom (AVGO) Rating Upgraded to Buy By Erste Group
Insider Monkey78d agobullish
Broadcom (AVGO) Rating Upgraded to Buy By Erste Group

Broadcom Inc. (NASDAQ:AVGO) is one of the 10 Best AI Stocks to Buy in June. On June 5, TheFly reported that the Erste Group upgraded its rating on Broadcom to Buy from Hold, noting that the company is growing much faster than its sectoral peers. The analyst expressed optimism for the stock, emphasizing that it […]

Is Microsoft (MSFT) One of the Best AI Stocks to Buy in June?
Insider Monkey78d agobullish
Is Microsoft (MSFT) One of the Best AI Stocks to Buy in June?

Microsoft Corporation (NASDAQ:MSFT) is one of the 10 Best AI Stocks to Buy in June. On June 7, Investing.com reported that UBS maintained Buy ratings on three major cloud providers, including Microsoft, driven by their revenue growth. The analyst noted that the combined cloud revenues of Microsoft, Amazon, and Oracle totaled $84.8 billion in the […]

Amazon.com Inc. (AMZN) Buy Rating Reiterated by BofA Securities
Insider Monkey78d agobullish
Amazon.com Inc. (AMZN) Buy Rating Reiterated by BofA Securities

Amazon.com, Inc. (NASDAQ:AMZN) is one of the 10 Best AI Stocks to Buy in June. On June 6, Investing.com reported that BofA Securities reiterated its $310 price target and Buy rating on Amazon, driven by developments in the company’s Leo satellite internet project. The analyst noted that Amazon is approaching an operational tipping point in […]

3 Reasons H is Risky and 1 Stock to Buy Instead
StockStory78d agobullish
3 Reasons H is Risky and 1 Stock to Buy Instead

Since June 2021, the S&P 500 has delivered a total return of 74.9%. But one standout stock has nearly doubled the market - over the past five years, Hyatt Hotels has surged 139% to $193.68 per share. Its momentum hasn’t stopped as it’s also gained 27.4% in the last six months, beating the S&P by 19.4%.

Is Coupang (CPNG) a Buy as Wall Street Analysts Look Optimistic?
Zacks78d agobullish
Is Coupang (CPNG) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Coupang (CPNG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

3 Reasons ASLE is Risky and 1 Stock to Buy Instead
StockStory78d agobullish
3 Reasons ASLE is Risky and 1 Stock to Buy Instead

AerSale currently trades at $6.42 per share and has shown little upside over the past six months, posting a small loss of 4.5%. The stock also fell short of the S&P 500’s 8% gain during that period.

Is It Time To Rethink Southern Copper (SCCO) After Its 87% One Year Surge?
Simply Wall St.78d agobullish
Is It Time To Rethink Southern Copper (SCCO) After Its 87% One Year Surge?

If you are wondering whether Southern Copper's current share price still reflects good value after its long run, the next sections will unpack what the numbers are really saying about the stock. The stock closed at US$170.48, with returns of 87.1% over the past year and 16.8% year to date, even though the price has fallen 12.4% over the last week and 7.1% over the past month. Recent coverage has focused on Southern Copper as a key copper producer at a time when investors are paying close...